10/08/2021

**Gynecology**

**CERVICAL CANCER**

- **Newly Diagnosed**
  - eIRB# 21007
  - Wee-1 inhibition prior to primary surgery for newly diagnosed ovarian cancer

- **First-line/Maintenance**
  - No current studies

- **Recurrent, Platinum-Sensitive**

- **Recurrent, Platinum-Resistant**

**OVARIAN (or FALLOPIAN, PERITONEAL) CANCER**

- **Newly Diagnosed**
  - DUO-E/GOG 3041: First-line chemotherapy with durvalumab followed by maintenance durvalumab with or without olaparib in newly diagnosed or recurrent endometrial cancer
  - eIRB# 21271

- **Recurrent, Platinum-Sensitive**

- **Recurrent, Platinum-Resistant**

**ENDOMETRIAL (UTERINE) CANCER**

- **Newly Diagnosed**
  - DUO-E/GOG 3041: First-line chemotherapy with durvalumab followed by maintenance durvalumab with or without olaparib in newly diagnosed or recurrent endometrial cancer
  - eIRB# 21271

- **Recurrent, Platinum-Sensitive**

- **Recurrent, Platinum-Resistant**

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php